Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06640569 · ClinicalTrials.gov registry record

Preliminary Characterization of Commercial Kratom Extract Products

A clinical trial of Kratom Pharmacodynamics and Kratom Pharmacokinetics, sponsored by Johns Hopkins University.

Recruiting
Registry status
16
Enrollment target
2
Study locations

NCT06640569: Recruiting study of Kratom Pharmacodynamics and Kratom Pharmacokinetics, sponsored by Johns Hopkins University.

NCT06640569 is a study of Kratom Pharmacodynamics and Kratom Pharmacokinetics that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 16 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06640569, a study of Kratom Pharmacodynamics and Kratom Pharmacokinetics, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
16 participants
Enrollment target
2
Study locations

Study Summary

To understand the acute subjective, physiological, and cognitive effects of commercial kratom extract products among US adults who consume these products regularly, and to understand how these products are metabolized by the human body.

Primary Outcome

Drug Effects Questionnaire (DEQ) visual analogue scale (0-100) rating for DEQ item "feeling" effects and "liking" effects. 0 is the measure of least impactful 'effect'.

Study Locations (2)

Maryland

  • Johns Hopkins University Behavioral Pharmacology Research Unit - Baltimore
  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2024-11-11
Est. Completion 2028-11-01
Johns Hopkins University

1,448 total trials

What NCT06640569 shows while recruiting

NCT06640569 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.

The record links to 2 conditions, with Kratom Pharmacodynamics appearing as the primary indexed condition, and to 0 interventions.

NCT06640569 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06640569 about?

NCT06640569 is a clinical study titled "Preliminary Characterization of Commercial Kratom Extract Products". To understand the acute subjective, physiological, and cognitive effects of commercial kratom extract products among US adults who consume these products regularly, and to understand how these products are metabolized by the human body.

What is the current status of trial NCT06640569?

This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2024-11-11. Estimated completion is 2028-11-01.

What conditions does trial NCT06640569 study?

This clinical trial studies the following conditions: Kratom Pharmacodynamics, Kratom Pharmacokinetics.

Who is sponsoring clinical trial NCT06640569?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06640569 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kratom Pharmacodynamics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06640569, the US trial registry maintained by the National Library of Medicine. NCT06640569 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.